Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD33 CAR T cells VCAR33

A preparation of allogeneic T lymphocytes, derived from the same matched healthy donor who provided a stem cell transplant and transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) specific for the CD33 antigen, with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic anti-CD33 CAR T cells VCAR33 specifically recognize and kill CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic anti-CD33 CAR-T cells VCAR33 donor-derived anti-CD33 CAR T cells VCAR33
Code name:	VCAR 33 VCAR-33 VCAR33

allogeneic anti-CD33 CAR T cells VCAR33

Search NCI's Drug Dictionary